Muscle Response to High Intensity Interval Resistance Training (HIIRT) (HIIRT)

March 24, 2020 updated by: Antonio Paoli, University of Padova

Effects of Exercise Intensity and Rest Intervals on Intracellular Signals and Anabolic Response of Skeletal Muscle to Resistance Training

Resistance training (RT) is one of the most important stimuli for muscle hypertrophy and it plays an important role on weight loss and fatty acid oxidation increase. RT affects anabolic pathways but the differences among various training techniques has been till now were poorly investigated. The aim of this study was to compare the effect of two different intensity of training, high-intensity interval resistance training (HIIRT) and traditional resistance training (TRT), on muscle signalling pathway.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Nine young healthy subjects performed HIIRT and TRT protocol in two different moments and with different legs. HIIRT technique consisted of three sets of: 6 repetitions at 6RM (6 repetitions maximum) and then 20 seconds of rest and 2/3 repetitions (until exhaustion) repeated for 3 times with 2'30" rest between sets; while TRT consisted of 3 sets of 15 reps with 75 sec of rest between sets. Biopsies from the vastus lateralis were taken at baseline (pre), immediately (0h) at the end of training, 6 hours (6h) and 24 hours (24h) after training. Western blot and RT-PCR mRNA (Reverse transcriptase-polymerase chain reaction) analysis were performed to assess muscle signalling pathway activation

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
9

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
      • Padova, Italy, 35131
        • Nutrition and Exercise Lab, DSB, University of Padova

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

20 years to 30 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • moderate active
  • experience with resistance training

Exclusion Criteria:

  • history of recent myocardial infarction,
  • severe cardiac arrhythmia,
  • unstable angina,
  • poorly controlled hypertension,
  • poorly controlled diabetes mellitus,
  • frequent or complex ventricular ectopy which might interfere with one's ability to adhere to exercise protocols

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
EXPERIMENTAL: High Intensity Interval Resistance Training (HIIRT)
HIIRT technique consisted of three sets of: 6 repetitions at 80% 1RM (1 repetition maximum) and then 20 seconds of rest and 2/3 repetitions (until exhaustion) repeated for 3 times with 2'30" rest between sets; while TRT consisted of 3 sets of 15 reps with 75 sec of rest between sets.
Other: High Intensity Interval Resistance Training
Subjects trained one leg with HIIRT
ACTIVE_COMPARATOR: Traditional Resistance Training (TRT)
TRT protocol performed 3 series of 15 repetitions at 60% 1RM with 75" of rest between sets.
Other: Traditional Resistance Training
Subjects trained the other leg with HIIRT

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
pAMPKThr172 in skeletal muscle tissue measured by immunoblot
Time Frame: 24 hours
measurement of pAMPKThr172 in skeletal muscle tissue taken by biopsy
24 hours
pERK 1/2Thr202/Tyr204 in skeletal muscle tissue measured by immunoblot
Time Frame: 24 hours
measurement of pERK 1/2Thr202/Tyr204 in skeletal muscle tissue taken by biopsy
24 hours
pS6Ser235/236 in skeletal muscle tissue measured by immunoblot
Time Frame: 24 hours
measurement of pS6Ser235/236 in skeletal muscle tissue taken by biopsy
24 hours
p4EBP1Thr37/46 in skeletal muscle tissue measured by immunoblot
Time Frame: 24 hours
measurement of p4EBP1Thr37/46 in skeletal muscle tissue taken by biopsy
24 hours
ACC (acetyl-coenzyme A carboxylase) phosphorylation in skeletal muscle tissue measured by immunoblot
Time Frame: 24 hours
ACC phosphorylation in skeletal muscle tissue taken by biopsy
24 hours
IGF-1 mRNA (messenger ribonucleic acid) in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
IGF-1 mRNA in skeletal muscle tissue taken by biopsy
24 hours
IGF-1ea (insulin like growth factor) mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hoursn
IGF-1ea mRNA in skeletal muscle tissue taken by biopsy
24 hoursn
MGF (mechanical growth factor) mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
MGF mRNA in skeletal muscle tissue taken by biopsy
24 hours
STARS mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hoursn
STARS mRNA in skeletal muscle tissue taken by biopsy
24 hoursn
Myogenin mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
Myogenin mRNA in skeletal muscle tissue taken by biopsy
24 hours
IL-6 (interleukin 6) mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
IL-6 mRNA in skeletal muscle tissue taken by biopsy
24 hours
PGC1a4 (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 4) mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
PGC1a4 mRNA in skeletal muscle tissue taken by biopsy
24 hours
PGC1a (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha) mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
PGC1a mRNA in skeletal muscle tissue taken by biopsy
24 hours
Atrogin mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
Atrogin mRNA in skeletal muscle tissue taken by biopsy
24 hours
Beclin mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
Beclin mRNA in skeletal muscle tissue taken by biopsy
24 hours
Myostatin mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
Myostatin mRNA in skeletal muscle tissue taken by biopsy
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Padova

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
University of Roma La Sapienza

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Antonio Paoli, MD, University of Padova

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 1, 2012

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 15, 2012

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 10, 2013

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 19, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 24, 2020

First Posted (ACTUAL)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 25, 2020

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 24, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2020

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • HIIRT12

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings